Page 20 - Flipbook
P. 20
PROfound STUDY DESIGN
Olaparib 300 mg bid Primary Endpoint
n=162
Cohort A:
BRCA1, BRCA2 or ATM Radiographic progression-
N=245 Physician’s choice ‡ free survival
Eligibility criteria n=83
• mCRPC with disease
progression on prior
abiraterone or
enzalutamide
• Alterations in ≥1 of any
qualifying gene with a Olaparib 300 mg bid
role in HRR* n=94
Cohort B:
Other alterations
N=142 Physician’s choice ‡
n=48
HRR = Homologous Recombination Repair:
